March 24, 2010 (FinancialWire) — Nektar Therapeutics (NASDAQ: NKTR) presented preliminary PFS data from a Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women with platinum-resistant ovarian cancer, demonstrating a median PFS of 21.0 weeks in women who received NKTR-102 once every 21 days and a median PFS of 12.2 weeks in women who received NKTR-102 once every 14 days.

Other recent FinancialWire(tm) news items pertaining to the oncology and stem cell sectors today include Cell Therapeutics, Inc. (NASDAQ: CTIC) go to http://www.financialwire.net/?s=%22%28NASDAQ%3A+CTIC%29%22), BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) (go to http://www.financialwire.net/?s=%22%28NASDAQ%3A+BPAX%29%22), Myriad Genetics, Inc. (NASDAQ: MYGN) (go to http://www.financialwire.net/?s=%22%28NASDAQ%3A+MYGN%29%22), Nektar Therapeutics (NASDAQ: NKTR) (go to http://www.financialwire.net/?s=%22%28NASDAQ%3A+NKTR%29%22), Genomic Health, Inc. (NASDAQ: GHDX) (go to http://www.financialwire.net/?s=%22%28NASDAQ%3A+GHDX%29%22), Entest BioMedical, Inc. (OTCBB: ENTB) (go to http://www.financialwire.net/?s=%22%28OTCBB%3A+ENTB%29%22), and others.

Source: Zangani Investor Community (http://www.investrend.com/about/zangani).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website(http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Source of original content for this article: (http://www.zangani.com/node/4024).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.